Business Standard

A COMMERCIAL FEATURE

What's this ?

Commercial Feature is a Business Standard Digital Marketing Initiative.

The Editorial/Content team at Business Standard has not contributed to writing or editing these articles.

For further information, please write to assist@bsmail.in

AstraZeneca sells antacid brand Neksium to Pfizer India for Rs 75 cr

Deal to help Pfizer, which also owns Gelusil brand, strengthen its presence in gastrointestinal area

BS B2B Bureau  |  Mumbai 

Pfizer to acquire oncology specialist Medivation for $ 14 bn

AB, Sweden, has sold its brand to Ltd, which also owns brand, for Rs 75 crore. The transaction is subject to completion of requisite clearances. 

Launched in India in 2006, is one the leading brands in the anti-peptic ulcerant space. Neksium, with the active ingredient esomeprazole belongs to a class of pharmaceutical preparations called proton pump inhibitors (PPI), which are used effectively for reducing the acid secretion in the stomach. It is widely prescribed for the treatment of conditions across the acid peptic disorders (APD) spectrum. 

“The acquisition is aligned with our stated ambition of portfolio expansion through organic and inorganic growth in our focus therapy areas. With this acquisition, we will accelerate our growth and strengthen our leadership position in the gastrointestinal (GI) therapy area,” commented S Sridhar, managing director, Ltd.

With brands such as & Mucaine, Ltd has been providing effective solutions in the space for over 30 years. “The company is uniquely well placed to grow the brand further through its existing reach, coverage and equity in the GI therapy area,” added in a press release.

RECOMMENDED FOR YOU

AstraZeneca sells antacid brand Neksium to Pfizer India for Rs 75 cr

Deal to help Pfizer, which also owns Gelusil brand, strengthen its presence in gastrointestinal area

Deal to help Pfizer, which also owns Gelusil brand, strengthen its presence in gastrointestinal area
AB, Sweden, has sold its brand to Ltd, which also owns brand, for Rs 75 crore. The transaction is subject to completion of requisite clearances. 

Launched in India in 2006, is one the leading brands in the anti-peptic ulcerant space. Neksium, with the active ingredient esomeprazole belongs to a class of pharmaceutical preparations called proton pump inhibitors (PPI), which are used effectively for reducing the acid secretion in the stomach. It is widely prescribed for the treatment of conditions across the acid peptic disorders (APD) spectrum. 

“The acquisition is aligned with our stated ambition of portfolio expansion through organic and inorganic growth in our focus therapy areas. With this acquisition, we will accelerate our growth and strengthen our leadership position in the gastrointestinal (GI) therapy area,” commented S Sridhar, managing director, Ltd.

With brands such as & Mucaine, Ltd has been providing effective solutions in the space for over 30 years. “The company is uniquely well placed to grow the brand further through its existing reach, coverage and equity in the GI therapy area,” added in a press release.
image
Business Standard
177 22

AstraZeneca sells antacid brand Neksium to Pfizer India for Rs 75 cr

Deal to help Pfizer, which also owns Gelusil brand, strengthen its presence in gastrointestinal area

AB, Sweden, has sold its brand to Ltd, which also owns brand, for Rs 75 crore. The transaction is subject to completion of requisite clearances. 

Launched in India in 2006, is one the leading brands in the anti-peptic ulcerant space. Neksium, with the active ingredient esomeprazole belongs to a class of pharmaceutical preparations called proton pump inhibitors (PPI), which are used effectively for reducing the acid secretion in the stomach. It is widely prescribed for the treatment of conditions across the acid peptic disorders (APD) spectrum. 

“The acquisition is aligned with our stated ambition of portfolio expansion through organic and inorganic growth in our focus therapy areas. With this acquisition, we will accelerate our growth and strengthen our leadership position in the gastrointestinal (GI) therapy area,” commented S Sridhar, managing director, Ltd.

With brands such as & Mucaine, Ltd has been providing effective solutions in the space for over 30 years. “The company is uniquely well placed to grow the brand further through its existing reach, coverage and equity in the GI therapy area,” added in a press release.

image
Business Standard
177 22